007390 - Naturecell Co., Ltd.

007390 Summary

Biopharma

Stock Price & Overview

₩23,950 +50 (+0.21%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩23,950 ≈ US$17 · Market cap ₩1.5tn (≈ $1.1bn)

007390 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Total Revenue	20.7	32.3	19.4	21.6	20.4	16.7
Cost of Revenue	11.3	15.4	11.2	12.2	11.0	9.1
Gross Profit	9.5	16.9	8.2	9.3	9.3	7.6
Selling, General & Administrative	13.1	16.3	18.5	18.8	16.8	14.0
Operating Income	-3.6	0.6	-10.3	-9.5	-7.5	-6.4
Finance Income	0.6	1.1	1.1	0.3	0.2	0.5
Finance Costs	0.2	0.2	2.2	2.8	16.9	1.3
Pretax Income	-2.8	1.4	-11.6	-8.9	-30.0	-18.9
Income Tax Expense	0.1	0.1	0.1	—	—	—
Net Income	-2.8	1.2	-11.7	-6.8	-32.0	-18.9
Total Comprehensive Income	-3.0	1.3	-12.5	-8.3	-31.5	-19.2
Interest Income	—	—	—	0.3	0.1	0.3
Interest Expense	—	—	—	1.7	0.8	0.5

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Total Assets	74.7	72.0	68.4	94.0	69.6	85.7
Current Assets	28.9	42.0	40.6	67.2	42.9	56.3
Cash & Cash Equivalents	16.8	28.4	29.9	31.3	32.6	41.5
Inventories	5.9	3.0	3.2	3.1	3.2	3.1
Trade Receivables	5.0	9.8	4.4	8.7	7.1	5.1
Non-current Assets	45.9	30.0	27.8	26.9	26.7	29.4
Property, Plant & Equipment	27.4	12.1	11.2	8.6	6.1	6.7
Intangible Assets	—	—	—	2.9	3.1	3.2
Total Liabilities	11.7	7.4	7.0	36.9	8.8	23.1
Current Liabilities	8.7	4.1	4.2	35.8	6.6	20.5
Non-current Liabilities	3.0	3.2	2.8	1.1	2.2	2.6
Total Equity	63.0	64.6	61.4	57.2	60.8	62.7
Share Capital	32.2	32.2	32.1	31.3	31.3	30.6
Retained Earnings	-74.2	-72.1	-73.2	-61.1	-54.4	-21.8

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Cash from Operating Activities	0.2	1.5	-2.1	-14.9	-10.1	-5.4
Cash from Investing Activities	-16.2	-3.7	15.6	-15.3	4.8	15.5
Purchase of Property, Plant & Equipment	16.5	3.1	6.1	-3.8	-0.4	-2.7
Cash from Financing Activities	4.9	0.2	-14.9	29.1	-3.7	10.3
Net Change in Cash	-11.6	-1.5	-1.4	-1.3	-8.9	20.3

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	6.2	4.1	6.4	3.9	6.4	4.1	7.7	5.8	9.6	9.1
Cost of Revenue	2.7	2.2	2.8	2.7	3.0	2.8	4.4	3.2	4.0	3.8
Gross Profit	3.5	1.9	3.5	1.2	3.4	1.3	3.4	2.6	5.6	5.3
Selling, General & Administrative	4.2	3.2	3.8	2.6	3.7	3.0	3.2	3.6	4.3	5.2
Operating Income	-0.7	-1.3	-0.3	-1.4	-0.3	-1.7	0.2	-1.0	1.3	0.1
Finance Income	0.2	0.2	0.1	0.2	-0.1	0.4	0.3	0.3	0.2	0.2
Finance Costs	0.2	0.2	0.1	0.0	0.1	0.0	0.0	-0.2	0.2	0.2
Pretax Income	-0.6	-1.1	0.4	-1.3	-0.7	-1.2	0.4	-0.5	1.3	0.2
Income Tax Expense	0.0	—	0.1	-0.0	0.0	—	0.1	0.0	0.0	0.0
Net Income	-0.6	-1.1	0.3	-1.3	-0.7	-1.2	0.3	-0.5	1.3	0.2
Total Comprehensive Income	-0.2	-0.0	0.2	-1.0	-0.9	-1.3	0.4	-0.6	1.1	0.4
Interest Income	—	—	—	—	—	—	—	—	—	0.0

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	88.6	86.7	74.7	71.3	72.0	70.8	72.0	70.9	71.8	69.7
Current Assets	39.9	40.6	28.9	39.5	40.3	39.6	42.0	40.8	41.5	41.8
Cash & Cash Equivalents	21.3	28.3	16.8	26.7	27.7	22.9	28.4	24.8	26.7	29.9
Inventories	5.8	6.6	5.9	5.8	4.0	3.4	3.0	3.6	3.7	2.5
Trade Receivables	9.6	4.7	5.0	5.6	5.0	9.9	9.8	8.9	6.8	6.8
Non-current Assets	48.6	46.1	45.9	31.8	31.7	31.2	30.0	30.0	30.3	27.9
Property, Plant & Equipment	29.9	28.0	27.4	12.4	13.5	13.6	12.1	13.7	13.8	11.1
Intangible Assets	—	—	—	2.4	2.4	2.5	2.5	2.6	2.6	2.6
Total Liabilities	25.6	23.7	11.7	8.6	8.4	7.3	7.4	6.8	8.5	7.7
Current Liabilities	22.7	21.0	8.7	4.4	4.2	3.9	4.1	3.9	5.6	5.0
Non-current Liabilities	2.9	2.7	3.0	4.2	4.2	3.5	3.2	2.9	2.9	2.7
Total Equity	62.9	63.1	63.0	62.7	63.7	63.5	64.6	64.1	63.3	62.0
Share Capital	32.2	32.2	32.2	32.2	32.2	32.2	32.2	32.2	32.1	32.1
Retained Earnings	-75.7	-75.2	-74.2	-75.2	-74.1	-73.4	-72.1	-72.3	-71.8	-72.8

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	-3.2	-0.8	0.5	-3.3	4.5	-1.6	1.3	-2.6	11.3	-8.4
Cash from Investing Activities	-3.5	0.5	-14.7	2.4	-0.0	-3.8	2.3	-0.1	-14.6	8.7
Purchase of Property, Plant & Equipment	0.6	0.0	14.9	0.1	0.1	1.4	0.2	5.7	-2.8	0.0
Cash from Financing Activities	-0.3	11.7	4.8	-0.2	0.6	-0.3	-0.2	1.0	-0.3	-0.3
Net Change in Cash	-7.0	11.6	-9.9	-1.0	4.7	-5.4	3.5	-1.9	-3.2	0.0

Consolidated (CFS), from DART. 6 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

007390 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	20.7	-35.9%	-1.3%	+4.4%	—
Operating income	-3.6	—	—	—	—
Net income	-2.8	—	—	—	—
EPS	₩-44	—	—	—	—
Operating cash flow	0.2	-89.6%	—	—	—
Shareholders' equity	63.0	-2.5%	+3.3%	+0.1%	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

007390 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	45.6%	52.3%	42.3%	43.4%	45.9%	45.5%
Operating margin	-17.6%	1.8%	-53.1%	-44.1%	-36.8%	-38.3%
Net margin	-13.7%	3.8%	-60.4%	-31.6%	-157.4%	-112.9%
Return on equity	-4.4%	1.9%	-19.7%	-11.5%	-51.9%	-30.1%
Return on assets	-3.9%	1.7%	-14.4%	-8.3%	-41.2%	-22.0%
Operating cash flow / revenue	0.8%	4.7%	-11.0%	-69.0%	-49.9%	-32.4%
Capex / revenue	79.8%	9.6%	31.6%	17.6%	1.9%	16.2%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 007390

Symbol	Last Price
140410Mezzion Pharma Co., Ltd.	₩65,000 +0.0%
068760Celltrion Pharm, Inc.	₩40,850 +0.0%
006280GC Biopharma Corp.	₩127,600 +0.5%
950160Kolon Tissue Gene, Inc.	₩17,100 +1.1%
039200Oscotec, Inc.	₩36,600 +1.9%
069620Daewoong Pharma	₩116,100 +1.1%
290650L & C BIO Co., Ltd.	₩47,900 -1.4%
127120JS Link	₩33,600 +12.4%
475830Orum Therapeutics, Inc.	₩55,900 +2.6%
195940HK inno.N Corporation	₩42,050 +0.7%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.